Synthesis and biological evaluation of the new 1,3-dimethylxanthine derivatives with thiazolidine-4-one scaffold by unknown
Constantin et al. Chemistry Central Journal  (2017) 11:12 
DOI 10.1186/s13065-017-0241-0
RESEARCH ARTICLE
Synthesis and biological evaluation 
of the new 1,3-dimethylxanthine derivatives 
with thiazolidine-4-one scaffold
Sandra Constantin1, Florentina Geanina Lupascu1, Maria Apotrosoaei1, Ioana Mirela Vasincu1, Dan Lupascu1, 
Frederic Buron2, Sylvain Routier2* and Lenuta Profire1*
Abstract 
Background: The xanthine structure has proved to be an important scaffold in the process of developing a wide 
variety of biologically active molecules such as bronchodilator, hypoglycemiant, anticancer and anti-inflammatory 
agents. It is known that hyperglycemia generates reactive oxygen species which are involved in the progression of 
diabetes mellitus and its complications. Therefore, the development of new compounds with antioxidant activity 
could be an important therapeutic strategy against this metabolic syndrome.
Results: New thiazolidine-4-one derivatives with xanthine structure have been synthetized as potential antidia-
betic drugs. The structure of the synthesized compounds was confirmed by using spectral methods (FT-IR, 1H-NMR, 
13C-NMR, 19F-NMR, HRMS). Their antioxidant activity was evaluated using in vitro assays: DPPH and ABTS radical 
scavenging ability and phosphomolybdenum reducing antioxidant power assay. The developed compounds showed 
improved antioxidant effects in comparison to the parent compound, theophylline. In the case of both series, the 
intermediate (5a–k) and final compounds (6a–k), the aromatic substitution, especially in para position with halogens 
(fluoro, chloro), methyl and methoxy groups, was associated with an increase of the antioxidant effects.
Conclusions: For several thiazolidine-4-one derivatives the antioxidant effect of was superior to that of their corre-
sponding hydrazone derivatives. The most active compound was 6f which registered the highest radical scavenging 
activity.
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Background
Discovered around 1888, xanthine scaffold, under the 
form of methylxanthine alkaloids, is naturally found in 
coffee (Coffea arabica) and tea (Camellia sinensis) and 
is associated with interesting biological activities, having 
bronchodilatatory (theophylline), diuretic (theobromine) 
and phychostimulant (caffeine) effects [1–3]. The new 
biologically active compounds such as bronchodilator [3], 
hypoglycemiant [4], anticancer [5] and anti-inflammatory 
[6] agents have been discovered by chemical modulation 
of this scaffold. An example of hypoglycemic agent is 
Linagliptin (Tradjenta®, Trajenta®), a DPP-4 inhibitor [7, 
8] which has been used in the USA for the treatment of 
diabetes mellitus type 2 since 2011. Its additional antioxi-
dant properties proved to be very useful in managing the 
vascular complications of diabetes (macrovascular-myo-
cardial infarction, angina pectoris, stroke and microvas-
cular-diabetic nephropathy and retinopathy, impotence, 
“diabetic foot”) [9].
Many recent research studies have focused on thia-
zolidine-4-one heterocycle, due to the role it plays in 
the synthesis [10] of new derivatives which showed 
significant biological activity as antidiabetic [11, 12], 
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antioxidant [13–15], anticonvulsant [16], anticancer [17], 
anti-inflammatory, analgesic [18], antimicrobial, anti-
fungal [19], antiviral [20], antihypertensive, antiarrhyth-
mic [21], anti-mycobacterial [22] and antiparasitic [23] 
effect. Moreover, the thiazolidinediones developed from 
this scaffold are important drugs used in treatment of 
diabetes mellitus type 2. Three thiazolidinediones (piogl-
itazone, rosiglitazone and lobeglitazone) are approved 
for diabetes mellitus therapy [24]. Although these drugs 
are a very effective for reducing hyperglycemia, they are 
also associated with serious side effects such as hepato-
toxicity, weight gain, macular edema and cardiovascular 
events [25, 26].
Diabetes mellitus is a chronic metabolic disorder con-
sidered a major health problem in the whole world. Every 
year 4 million people die from diabetes mellitus and 1.5 
million new cases are diagnosed. This disease is charac-
terized by hyperglycemia, a condition which, if not prop-
erly controlled, can lead to complications at the level of 
different organs. It mainly affects the eyes, the heart, the 
kidneys and the blood vessels. Hyperglycemia also gen-
erates reactive oxygen species (ROS) which can produce 
cell damages by means of different mechanism [27]. It has 
been proven that oxidative stress (an imbalance between 
the production of ROS and the scavenging ability of the 
body) holds a key role in the development of diabetes 
mellitus and its complications. The scavenging ability is 
closely related to the concentration of endogenous oxida-
tive enzymes such as catalase, glutathione peroxidase and 
superoxide dismutase [28].
In order to develop new compounds with antioxidant 
effects and potential applications in antidiabetic ther-
apy, new thiazolidine-4-one derivatives with xanthine 
structure have been synthesized. The structure of these 
compounds was proved by means of spectral methods 
(FT-IR, 1H-NMR, 13C-NMR, 19F-NMR, HRMS) and their 
antioxidant effects were evaluated using in  vitro assays: 
DPPH and ABTS radical scavenging ability and phospho-
molybdenum reducing antioxidant power assay.
Results and discussion
Chemistry
The new 1,3-thiazolidine-4-one derivatives were synthe-
sized according to Scheme 1. Theophylline (1,3-dimeth-
ylxanthine) 1, in the presence of sodium methoxide, 
gave the salt 2 in a quantitative yield; the salt in its turn 
reacted with ethyl chloroacetate and resulted in theo-
phylline-ethyl acetate 3 [4]. The reaction of the com-
pound 3 with an excess of hydrazine hydrate 64% resulted 
in a very good yield of theophylline hydrazide 4. Then, 
the condensation of the compound 4 with different aro-
matic aldehydes led to the formation of the correspond-
ing hydrazones 5a–k in satisfying yields [29, 30]. Finally, 
the cyclization of hydrazones (5a–k) in the presence of 
mercaptoacetic acid had as result thiazolidine-4-one 
derivatives 6a–k in moderate to excellent yields (Table 1). 
Totally were obtained 22 compounds from which 19 are 
new (8 hydrazones: 5b, 5d, 5e, 5g–5k and 11 thiazoli-
dine-4-ones: 6a–k).
The structure of the compounds was proved on the 
basis of the spectral data (IR, 1H-NMR,13C-NMR,19F-
NMR, HRMS) provided in the “Experimental section” 
part of the paper. The IR and NMR spectral data for com-
pounds 3 and 4 were previously presented [4].
The specific CH=N bond of hydrazone derivatives 
5a–k appeared in IR spectra in the region of 1544–
1609 cm−1. Other specific bands appeared in the region 
of 1635–1671  cm−1 (CO–NH) and 3034–3110  cm−1 (–
NH). The thiazolidine-4-one ring of the 6a–k derivatives 
was identified in the IR spectra by specific bands of C=O 
Scheme 1 Synthesis of compounds 6a–j. Reagents and conditions: (a) sodium, dry MeOH, r.t., overnight; (b) ethyl chloroacetate, EtOH/DMF (4:1.5), 
reflux, overnight; (c) hydrazine hydrate 64%, EtOH, reflux, 6 h; (d) aromatic aldehyde, EtOH, reflux, 2 h 30 min–48 h; (e) mercaptoacetic acid, toluene, 
heating 120 °C, 18 h
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and C–S bonds which appeared at 1682–1701 and 665–
699 cm−1, respectively.
In the 1H-NMR spectra of hydrazones 5a–k there were 
identified two sets of signals which corresponded to the 
two tautomer forms and were in dynamic equilibrium 
with each other. The proton from amide group (CO–NH) 
is responsible for the lactam-lactim tautomerism, obtain-
ing two forms: the hydrazone (lactam form, HN–C=O) 
and the tautomer (lactim form, N=C–OH). The ratio 
between tautomers ranged between 9:1 and 7:3, depend-
ing on the compound. The proton of the azomethine 
group (N=CH) resonated as a singlet at 7.96–8.38 ppm 
for one form and at 8.06–8.55  ppm for the other form. 
The proton of the amide group (CO–NH) appeared as a 
singlet at 11.55–11.83 ppm in the case of the hydrazone 
and at 11.63–11.83 ppm in the case of the tautomer form. 
The tautomerism was proved by 1H-NMR at 80 °C, when 
one set of signals was recorded.
The success of the cyclization process which resulted 
in the formation of the thiazolidine-4-one ring, was 
proved by means of 1H-NMR data. The proton from the 
N–CH–S group was recorded as a singlet between 5.75 
and 6.10 ppm while the protons of the methylene group 
(CH2–S) resonated as doublets of doublets or multiples 
in the interval between 3.63 and 3.80 ppm.
The structure of the synthesized compounds was 
strengthened by 13C-NMR data. The compounds 5a–k 
had two azomethine groups (N=CH), one from the 
theophylline part and another one from the hydrazone 
chain. The carbon signals of these groups were observed 
between 140.3 and 148.8  ppm. Moreover, the carbons 
from the thiazolidine-4-one ring appeared at 56.9–
61.7 ppm (N–CH–S) and 29.9–30.1 ppm (CH2–CO).
The fluorine atom from the structure of 5d and 6d, res-
onated in 19F-NMR spectra as a specific signal registered 
at −110.5 and −110.4  ppm in the case of the tautomer 
forms of hydrazone and at −110.2 ppm in the case of the 
thiazolidine-4-one derivatives.
The molecular mass of hydrazones 5a–k and of the 
corresponding thiazolidine-4-one derivatives, 6a–k, 
was probed by means of high resolution spectral mass. 
The spectral mass data coupled with the NMR data (1H-
NMR, 13C-NMR, 19F-NMR) proved the proposed struc-
ture for all synthesized compounds.
Biological evaluation
DPPH radical scavenging assay
2,2-Diphenyl-1-picrylhydrazyl (DPPH) assay is usu-
ally applied for the evaluation of the antioxidant activ-
ity of different compounds. The method is based on the 
reduction of DPPH, which is violet in methanol solution, 
to a pale yellow compound, under the action of an anti-
oxidant (proton donating agent). The absorbance of the 
yellow form is measured at 517 nm [31, 32]. The DPPH 
radical scavenging ability (%) of the theophylline–acethy-
drazide derivatives 5a–k was calculated at different con-
centrations (0.4, 0.8, 1.2, 1.6, 2.0 mg/mL). Higher values 
of the scavenging ability indicate a superior effectiveness 
of the scavenging radical potential. It was observed that 
the scavenging ability of the hydrazones increased with 
the concentration, the best inhibition rate being recorded 
at the highest concentration used (2 mg/mL). The most 
significant increase from 0.4 to 2  mg/mL was recorded 
for 5a (R=H). At the highest concentration used (2.0 mg/
mL) the inhibition rate ranged from 4.51  ±  0.36% for 
5c (R = 4-Cl) to 18.65 ± 0.43% for 5a (R=H) (Table 2). 
The inhibition rate of 5a was higher than that of theo-
phylline (1, 12.14  ±  0.20%). The compounds 5d (R=4-
F), 11.65  ±  0.19% and 5g (R=3-OCH3), 10.66  ±  0.19% 
showed a similar activity to theophylline. However, the 
hydrazone derivatives were less active than vitamin C 
which was used as positive control.
The scavenging ability of the theophylline-acethy-
drazide derivatives was improved by cyclization to the 
corresponding thiazolidine-4-one derivatives 6a–k. Their 
scavenging ability at different concentrations (0.4, 0.8, 
1.2, 1.6, 2.0 mg/mL) was higher than the value recorded 
for the corresponding hydrazones. The inhibition rate of 
6a–k was similar to the one of 5a–k and increased with 
the concentration, the best inhibition rate being recorded 
at the highest concentration used (2  mg/mL). At this 
concentration the best inhibition rate was shown by 6c 
(R=4-Cl) and 6k (R=4-CH3), with vlues of 77.53 ± 0.47% 
(EC50  =  1.1640  ±  0.0123  mg/mL) and 68.28  ±  0.19% 
(EC50 = 1.4389 ± 0.0130 mg/mL), respectively. In com-
parison to theophylline (1) these compounds were about 
6.5 times and six times more active. The most promising 
compound seemed to be 6f (R=4-OCH3), which had an 
inhibition rate of 64.50 ± 0.59% at 0.3 mg/mL, showing 
the best EC50 value (0.2212 ± 0.0011 mg/mL) (Table 3). 
These data supported the conclusion that the presence of 
the methoxy, chloro and methyl group in the para posi-
tion of the phenyl ring of the thiazolidine-4-one scaffold 
had a good influence on the radical scavenging activity.
A good influence was also showed by the presence 
of the fluoro group in para position and of the meth-
oxy group in ortho and meta position; the correspond-
ing compounds 6d (R=4-F), 6e (R=2-OCH3), 6g 
(R=3-OCH3) and 6j (2,3-OCH3) being about three time 
more active than theophylline. However all tested com-
pounds were less active than Vitamin C used as positive 
control.
ABTS radical scavenging ability
The radical of ABTS (2,2′-azino-bis-(3-ethylbenzothiazo-
line-6-sulfonic acid)), a blue chromophore (ABTS·+), was 
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Table 1 Synthesis of compounds 5 and 6
Entry No Compound 5 Yield (%) Entry No Compound 6 Yield (%)
1 5a 74 12 6a 50
2 5b 95 13 6b 30
3 5c 95 14 6c 29
4 5d 90 15 6d 28
5 5e 87 16 6e 33
6 5f 91 17 6f 37
7 5g 94 18 6g 50
8 5h 93 19 6h 50
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generated by oxidation with potassium persulfate. In the 
presence of hydrogen donating compounds, ABTS·+ was 
reduced and the corresponding form was quantitative 
measured by recording the absorbance value at 734  nm 
[33]. The scavenging ability of 5a–k and 6a–k at different 
concentrations (0.25, 0.5, 0.75, 1.0 mg/mL) was presented 
in Tables  4 and 6. In the theophylline-acethydrazide 
series the most active compounds were 5d (R=4-F) and 
5b (R=4-Br), registering EC50 values of 0.2084 ± 0.0013 
and 0.3662  ±  0.0030  mg/mL, respectively (Table  5). A 
good activity was also shown by 5c (R=4-Cl), 5i (R=2,4-
OCH3) and 5k (R=4-CH3).
At a concentration of 1  mg/mL the most active com-
pounds were 6d (R=4-F) and 6f (R=4-OCH3) for 
which the scavenging ability was 90.05  ±  0.07 and 
73.43 ±  0.56% (Table  6). A good scavenging ability was 
also shown by 6e (R=2-OCH3) and 6k (R=4-CH3). The 
data supported the conclusion that fluoro, methoxy 
(ortho, meta) and the methyl group exercised a positive 
influence on the ABTS scavenging activity. The EC50 val-
ues for these compounds were presented in Table 7. All 
compounds were less active than positive control.
For some thiazolidin-4-one derivatives (6a, 6e, 6f, 
6g, 6h, 6j) the ABTS scavenging activity was improved 
in comparison to that of the corresponding hydrazone 
derivatives at concentration of 1 mg/mL.
Table 1 continued
Entry No Compound 5 Yield (%) Entry No Compound 6 Yield (%)
9 5i 93 20 6i 6
10 5j 79 21 6j 54
11 5k 89 22 6k 52
Table 2 The DPPH scavenging ability (%) of  derivatives 
5a–k at 2 mg/mL





5a 18.65 ± 0.43 5g 10.66 ± 0.19
5b 9.79 ± 0.30 5h 4.01 ± 0.24
5c 4.51 ± 0.36 5i 9.08 ± 0.13
5d 11.65 ± 0.19 5j 5.90 ± 0.24
5e 5.90 ± 0.24 5k 5.56 ± 0.19
5f 5.64 ± 0.32
Theophylline 12.14 ± 0.20 Vitamin Ca 81.62 ± 0.21
Table 3 The DPPH scavenging ability (%) at  2  mg/mL 
and EC50 (mg/mL) of 6a–k
Data are mean ± SD (n = 3, p < 0.05)
EC50 (mg/mL): 






6a 27.99 ± 0.49 6g 35.05 ± 0.32
6b 13.11 ± 0.12 6h 24.60 ± 0.31
6c 77.53 ± 0.47a 6i 28.32 ± 0.18
6d 33.47 ± 0.42 6j 38.39 ± 0.28
6e 37.49 ± 0.45 6k 68.28 ± 0.19c
6fe 64.50 ± 0.59b
Theophylline 12.14 ± 0.20 Vitamin Cf 81.62 ± 0.21d
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Phosphomolybdenum reducing antioxidant power (PRAP) 
assay
Phosphomolybdenum reducing antioxidant assay, 
known as total antioxidant capacity assay, is a 
spectrophotometric method based on the formation of 
green colored phosphomolybdenum complex after the 
reduction of Mo(VI) to Mo(V) under the action of elec-
tron donating compounds in acidic medium [34]. An 
increase in optical density means a better total antioxi-
dant capacity.
In Figs.  1 and 2 there were presented the absorbance 
values of the tested compounds (5a–k, 6a–k) at differ-
ent concentrations (0.0291, 0.0582, 0.0872, 0.1163 and 
0.1745  mg/mL). As we expected, the absorbance of the 
tested compounds increased with the concentration, 
the highest value of absorbance/activity being recorded 
at 0.1745  mg/mL, the highest concentration used. The 
data expressed as EC50 values (mg/mL) were shown in 
Tables 8 and 9.
In the theophylline-acethydrazide serie (5a–k) all tested 
compounds were more active than theophylline (1). The 
most active were 5a (R=H, EC50 = 0.0618 ± 0.0007) and 
5g (R=3-OCH3, EC50 = 0.0645 ± 0.0009) (Table 8).
Some of thiazolidine-4-one derivatives showed an 
antioxidant capacity higher than that of the hydrazone 
derivatives, which proved that the presence of thiazoli-
dine ring had a significant effect on the phosphomolyb-
denum reducing antioxidant power (Fig. 2). The most 
active compounds were 6a (EC50 = 0.0503 ± 0.0008), 6j 
(EC50 = 0.0509 ± 0.0037), 6c (EC50 = 0.0585 ± 0.0007) 
and 6k (EC50  =  0.0597  ±  0.0018). These data sup-
ported that the best substitution of the aromatic ring 
attached to a thiazolidine-4-one cycle was represented 
by hydrogen (6a), 3,5-dimethoxy (6j), 4-chloro (6c) 
and 4-methyl (6k), respectively (Table  9). In compar-
ison to vitamin C (EC50  =  0.0148  ±  0.0001), used as 




The melting points were measured by using a Buchi Melt-
ing Point B-540 apparatus and they were uncorrected. 
The FT-IR spectra were recorded on a Thermo-Nicolet 
AVATAR 320 AEK0200713 FT-IR Spectrometer, at a res-
olution of 4 cm−1 after six scans in the 4000–500 cm−1. 
The spectra processing was carried out with the Omnic 
Spectra Software. The 1H-NMR (250, 400  MHz), 13C-
NMR (63, 101  MHz) and 19F-NMR (376  MHz) spectra 
were obtained on two types of Bruker Avance spectrom-
eter: 250 and 400 MHz, using tetramethylsilane as inter-
nal standard and DMSO-d6 and CDCl3 as solvents. The 
chemical shifts were shown in δ values (ppm). The mass 
spectra were registered by using a BrukerMaXis Ultra-
High Resolution Quadrupole Time-of-Flight Mass Spec-
trometer. The reactions were monitored by TLC, using 
pre-coated Kieselgel 60 F254 plates (Merck, Whitehouse 
Table 4 The ABTS scavenging ability (%) of  derivatives 
5a–k






5aa 20.65 ± 0.26 5ga 23.83 ± 0.43
5bb 70.20 ± 0.11 5ha 22.09 ± 0.23
5ca 62.74 ± 0.48 5ia 66.30 ± 0.32
5dc 57.39 ± 0.32 5ja 26.30 ± 0.31
5ea 27.21 ± 0.12 5ka 76.16 ± 0.45
5fa 29.21 ± 0.27
Theophyllinea 25.97 ± 0.27 Vitamin Cd 78.42 ± 0.40
Table 5 The ABTS scavenging ability (EC50, mg/mL) of  the 
most active compounds
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
5b 0.3362 ± 0.0030 5i 0.6718 ± 0.0026
5c 0.7187 ± 0.0039 5k 0.4224 ± 0.0040
5d 0.2084 ± 0.0013 Vitamin C 0.0028 ± 0.0001
Table 6 The ABTS scavenging ability (%) of  derivatives 
6a–k
a 0.004 mg/mL; Data are mean ± SD (n = 3, p < 0.05)
Sample Scavenging  
ability (%)
Sample Scavenging  
ability (%)
6a 30.68 ± 0.09 6g 29.39 ± 0.15
6b 12.95 ± 0.28 6h 26.43 ± 0.15
6c 12.59 ± 0.31 6i 32.03 ± 0.14
6d 90.05 ± 0.07 6j 47.13 ± 0.12
6e 66.00 ± 0.12 6k 57.36 ± 0.11
6f 73.43 ± 0.56
Theophylline 25.97 ± 0.27 Vitamin Ca 78.42 ± 0.40
Table 7 The ABTS scavenging ability (EC50, mg/mL) of  the 
most active compounds
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
6d 0.8352 ± 0.0005 6f 0.3805 ± 0.0032
6e 0.5880 ± 0.0017 6k 0.6789 ± 0.0024
Vitamin C 0.0028 ± 0.0001
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Station, NJ, USA) and the compounds were visualized 
using UV light. The absorbance for biological assays was 
measured using a GBC Cintra 2010 UV–VIS spectropho-
tometer at different wavelengths: 517, 734 and 695  nm. 
The values were recorded in Cintral Software.
Synthetic procedures
The synthesis of hydrazide derivatives (5a–k) The gen-
eral procedure used for the synthesis of theophylline-
acethydrazide derivatives and a part of their physical and 
chemical characteristics were described in our previous 
papers [29, 30]. The synthesis of the theophylline sodium 
salt 2, theophylline ethyl acetate 3 and theophylline 
acetyl-hydrazine 4, used as intermediaries in the synthesis 
of hydrazone derivatives 5a–k was performed according 
to the literature procedure and some of their physical and 
chemical characteristics were presented in our previous 
paper [4].
N-Benzylidene-2-(1,3-dimethylxanthin-7-yl)acethy‑
drazide (5a) Tautomeric mixture (8:2). 13C-NMR 
(101  MHz, DMSO-d6): δ  =  168.3/163.3(Cq), 154.9 
(Cq), 151.4 (Cq), 148.3/148.4 (Cq), 144.7/147.8 (CH=N), 
144.1/144.2 (CH=N), 134.3/134.4 (Cq), 130.5/130.6 
(CHAr), 129.3/129.2 (CHAr), 127.3/127.5 (CHAr), 
107.1/106.8 (Cq), 47.8/47.9 (N–CH2–CO), 29.9 (N–CH3), 
27.8/27.9 (N–CH3); HRMS (EI-MS): m/z calculated for 
C16H17N6O3 [M + H]+ 341.13567, found 341.13566.
N-(4-Bromobenzylidene)-2-(1,3-dimethylxanthin-
7-yl)acethydrazide (5b) Tautomeric mixture (8:2). 13C-
NMR (101 MHz, DMSO-d6): δ = 168.5 (2 × Cq), 154.9 
(Cq), 151.4 (Cq), 148.2/148.4 (Cq), 144.0/144.1 (CH=N), 
143.5/146.6 (CH=N), 133.5/133.7 (Cq), 132.2 (CHAr), 
129.2/129.4 (CHAr), 123.8/123.9 (Cq), 107.1/106.8 (Cq), 
47.8/47.9 (N–CH2–CO), 29.8 (N–CH3), 27.8 (N–CH3); 
HRMS (EI-MS): m/z calculated for C16H16BrN6O3 
[M + H]+ 419.04618, found 419.04610.
N-(4-Chlorobenzylidene)-2-(1,3-dimethylxanthin-7-yl)
acethydrazide (5c) Tautomeric mixture (8:2). 13C-NMR 
(101  MHz, DMSO-d6): δ  =  168.5/163.4 (Cq), 154.9 
(Cq), 151.5 (Cq), 148.3/148.4 (Cq), 144.1/144.2 (CH=N), 
143.5/146.5 (CH=N), 135.0/135.1 (Cq), 133.3/133.4 
(Cq), 129.4 (CHAr), 129.0/129.2 (CHAr), 107.2/106.9 (Cq), 
47.8/48.0 (N–CH2–CO), 29.9 (N–CH3), 27.9/27.8 (N–
CH3); HRMS (EI-MS): m/z calculated for C16H16ClN6O3 































































Fig. 2 The absorbance of derivatives 6a–k
Table 8 The phosphomolybdenum reducing antioxidant 
power (EC50, mg/mL) of 5a–k
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
5a 0.0618 ± 0.0007 5g 0.0645 ± 0.0009
5b 0.0912 ± 0.0016 5h 0.0773 ± 0.0003
5c 0.0731 ± 0.0016 5i 0.0826 ± 0.0020
5d 0.0944 ± 0.0018 5j 0.0831 ± 0.0007
5e 0.0824 ± 0.0012 5k 0.1015 ± 0.0045
5f 0.0746 ± 0.0003
Theophylline nd Vitamin C 0.0148 ± 0.0001
Table 9 The phosphomolybdenum reducing antioxidant 
power (EC50, mg/mL) of 6a–k
Data are mean ± SD (n = 3, p < 0.05)
nd undetected
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
6a 0.0503 ± 0.0008 6g 0.0640 ± 0.0003
6b 0.0668 ± 0.0017 6h 0.0760 ± 0.0015
6c 0.0585 ± 0.0007 6i 0.0735 ± 0.0016
6d 0.0620 ± 0.0023 6j 0.0509 ± 0.0037
6e 0.0764 ± 0.0042 6k 0.0597 ± 0.0018
6f 0.0742 ± 0.0007
Theophylline nd Vitamin C 0.0148 ± 0.0001
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N-(4-Fluorobenzylidene)-2-(1,3-dimethylxanthin-7-yl)
acethydrazide (5d) Tautomeric mixture (8:2). Yield 90%, 
white solid, m.p. 284–285  °C; IR (ATR diamond, cm−1): 
3110 (–NH–), 2971 (CHAr), 1636 (–CO–NH–), 1600 
(–CH=N), 1226 (C–F); 1H-RMN (400  MHz, DMSO-
d6): δ  =  11.78 (s, 1H, CO–NH), 8.05 (d, J  =  2.7  Hz, 
2H, CH=N)/8.22, 8.07 (s, 2H, CH=N), 7.83–7.73 (m, 
2H, Ar–H), 7.30 (t, J  =  8.3  Hz, 2H, Ar–H), 5.55/5.12 
(s, 2H, CH2–CO), 3.45 (s, 3H, N–CH3), 3.20 (s, 3H, N–
CH3); 13C-NMR (101  MHz, CDCl3): δ  =  173.1/169.4 
(Cq), 159.6/168.0 (Cq), 156.2/167.0 (Cq), 153.0/153.1 
(Cq), 148.8 (CH=N), 148.4 (CH=N), 135.7/135.8 (Cq), 
135.6/135.8 (Cq), 134.3/134.5 (CHAr), 134.3/134.5 (CHAr), 
121.2 (CHAr), 121.0 (CHAr), 111.9/111.6 (Cq), 52.5/52.6 
(N–CH2–CO), 34.6 (N–CH3), 32.6/32.7 (N–CH3); 19F-
RMN (376  MHz, CDCl3): δ  =  −110.5/−110.4 (s, 1F, 
Ar–F), HRMS (EI-MS): m/z calculated for C16H16FN6O3 
[M + H]+ 359.12624, found 359.12651.
N-(2-Methoxybenzylidene)-2-(1,3-dimethylxanthin-
7-yl)acethydrazide (5e) Tautomeric mixture (8:2). Yield 
86%, white solid, m.p. 274–275  °C; IR (ATR diamond, 
cm−1): 3034 (–NH–), 2974 (CHAr), 1648 (–CO–NH–), 
1600 (–CH=N), 1114 (O–C); 1H-RMN (400  MHz, 
DMSO-d6): δ  =  11.70 (s, 1H, CO–NH), 8.38/8.55 
(s, 1H, CH=N), 8.04/8.06 (s, 1H, CH=N), 7.86 (d, 
J =  7.6  Hz, 1H, Ar–H)/7.76 (d, J =  7.5  Hz, 1H, Ar–H), 
7.40 (t, J = 7.2 Hz, 1H, Ar–H), 7.09 (d, J = 8.3 Hz, 1H, 
Ar–H), 7.00 (t, J = 7.6 Hz, 1H, Ar–H), 5.52/5.09 (s, 2H, 
CH2–CO), 3.85 (s, 3H, O–CH3), 3.43 (s, 3H, N–CH3), 
3.18 (s, 3H, N–CH3); 13C-NMR (101  MHz, DMSO): 
δ = 168.2/163.1 (Cq), 158.1/158.2 (Cq), 154.8 (Cq), 151.4 
(Cq), 148.2/148.4 (Cq), 144.0/144.1 (CH=N), 140.3/143.3 
(CH=N), 132.0/132.1 (CHAr), 125.8/125.9 (CHAr), 
122.2/122.3 (Cq), 121.1 (CHAr), 112.2 (CHAr), 107.1/106.8 
(Cq), 56.1 (O–CH3), 47.8/47.9 (N–CH2–CO), 29.8 (N–
CH3), 27.8 (N–CH3); HRMS (EI-MS): m/z calculated for 
C17H19N6O4 [M + H]+ 371.14623, found 371.14591.
N-(4-Methoxybenzylidene)-2-(1,3-dimethylxanthin-
7-yl)acethydrazide (5f) Tautomeric mixture (8:2). Yield 
91%, white solid, m.p. 250–251  °C; IR (ATR diamond, 
cm−1): 3094 (–NH–), 2961 (CHAr), 1659 (–CO–NH–), 
1606 (–CH=N), 1125 (O–C); 1H-RMN (400  MHz, 
DMSO-d6): δ = 11.63 (s, 1H, CO–NH), 8.06/8.16 (s, 1H, 
CH=N), 7.99/8.07 (s, 1H, CH=N), 7.67 (d, J =  8.7  Hz, 
2H, Ar–H)/7.64 (d, J  =  9.0  Hz, 2H, Ar–H), 7.02 (d, 
J  =  8.7  Hz, 2H, Ar–H), 5.53/5.10 (s, 2H, CH2–CO), 
3.80 (d, J =  3.3  Hz, 3H, O–CH3), 3.46 (s, 3H, N–CH3), 
3.20 (s, 3H, N–CH3); 13C-NMR (101  MHz, DMSO-
d6): δ  =  168.1/163.0 (Cq), 161.2/161.3 (Cq), 154.9 (Cq), 
151.4 (Cq), 148.3/147.6 (Cq), 144.6 (CH=N), 144.1/144.2 
(CH=N), 128.9/129.2 (CHAr), 126.2/126.9 (Cq), 114.8 
(CHAr), 107.1/106.8 (Cq), 55.7 (O–CH3), 47.8/47.9 (N–
CH2–CO), 29.9 (N–CH3), 27.8/27.9 (N–CH3); HRMS 
(EI-MS): m/z calculated for C17H19N6O4 [M  +  H]+ 
371.14623, found 371.14586.
N-(3-Methoxybenzylidene)-2-(1,3-dimethylxanthin-
7-yl)acethydrazide (5g) Tautomeric mixture (8:2). Yield 
94%, white solid, m.p. 238–239  °C; IR (ATR diamond, 
cm−1): 3075 (–NH–), 2965 (CHAr), 1660 (–CO–NH–), 
1598 (–CH=N), 1157 (C–O); 1H-RMN (400  MHz, 
DMSO-d6): δ  =  11.77 (s, 1H, CO–NH), 8.06/8.19 (s, 
1H, CH=N), 8.02/8.07 (s, 1H, CH=N), 7.40–7.33 (m, 
1H, Ar–H), 7.28 (t, J  =  10.0  Hz, 2H, Ar–H), 7.01 (d, 
J  =  7.7  Hz, 1H, Ar–H), 5.55/5.12 (s, 2H, CH2–CO), 
3.80/3.79 (s, 3H, O–CH3), 3.46 (s, 3H, N–CH3), 3.20 
(s, 3H, N–CH3); 13C-NMR (101  MHz, DMSO-d6): 
δ = 168.4/163.3 (Cq), 160.0/159.9 (Cq), 154.9 (Cq), 151.5 
(Cq), 148.3/148.4 (Cq), 144.6/147.6 (CH=N), 144.1/144.2 
(CH=N), 135.7/135.8 (Cq), 130.4 (CHAr), 120.0/120.4 
(CHAr), 116.5/116.74 (CHAr), 111.9 (CHAr), 107.1/106.8 
(Cq), 55.6 (O–CH3), 47.8/47.9 (N–CH2–CO), 29.9 (N–
CH3), 27.8 (N–CH3); HRMS (EI-MS): m/z calculated for 
C17H19N6O4 [M + H]+ 371.14623, found 371.14612.
N-(2,3-Dimethoxybenzylidene)-2-(1,3-dimethylxan‑
thin-7-yl)acethydrazide (5h) Tautomeric mixture (8:2). 
Yield 93%, white solid, m.p. 252–253  °C; IR (ATR dia-
mond, cm−1): 3085 (–NH–), 2945 (CHAr), 1669 (–CO–
NH–),1606 (–CH=N), 1061 (O–C); 1H-RMN (400 MHz, 
DMSO-d6): δ = 11.72 (s, 1H, CO–NH), 8.33/8.48 (s, 1H, 
CH=N), 8.05/8.07 (s, 1H, CH=N), 7.49–7.44/7.39–7.36 
(m, 1H, Ar–H), 7.12 (d, J = 3.7 Hz, 2H, Ar–H), 5.53/5.11 
(s, 2H, CH2–CO), 3.84 (s, 3H, O–CH3), 3.78/3.80 (s, 3H, 
O–CH3), 3.45 (s, 3H, N–CH3), 3.19 (s, 3H, N–CH3); 13C-
NMR (101 MHz, DMSO-d6): δ = 168.8/163.2 (Cq), 154.9 
(Cq), 153.1/153.0 (Cq), 151.4 (Cq), 148.4 (Cq), 144.3/148.4 
(CH=N), 144.0/144.2 (CH=N), 140.5/143.3 (CHAr), 
127.7/127.8 (Cq), 124.8 (CHAr), 117.2/117.4 (CHAr), 
114.7/114.8 (CHAr), 107.1/106.8 (Cq), 61.6 (O–CH3), 
56.2 (O–CH3), 47.8/47.9 (N–CH2–CO), 29.9 (N–CH3), 
27.8/27.9 (N–CH3); HRMS (EI-MS): m/z calculated for 
C18H21N6O5 [M + H]+ 401.15679, found 401.15654.
N-(2,4-Dimethoxybenzylidene)-2-(1,3-dimethylxan‑
thin-7-yl)acethydrazide (5i) Tautomeric mixture (8:2). 
Yield 93%, white solid, m.p. >250  °C; IR (ATR diamond, 
cm−1): 3108 (–NH–), 2944 (CHAr), 1658 (–CO–NH–), 
1601 (–CH=N), 1135 (O–C); 1H-RMN (400  MHz, 
DMSO-d6): δ = 11.55/11.67 (s, 1H, CO–NH), 8.29/8.46 
(s, 1H, CH=N), 8.04/8.06 (s, 1H, CH=N), 7.79 (d, 
J =  8.6  Hz, 1H, Ar–H)/7.70 (d, J =  8.5  Hz, 1H, Ar–H), 
6.65–6.61 (m, 2H, Ar–H)/6.60 (d, 2H, Ar–H), 5.50/5.07 
(s, 2H, CH2–CO), 3.85 (s, 3H, O–CH3), 3.82/3.81 (s, 
3H, O–CH3), 3.45 (s, 3H, N–CH3), 3.19 (s, 3H, N–CH3); 
13C-NMR (101  MHz, DMSO-d6): δ =  167.9/163.0 (Cq), 
162.8/162.7 (Cq), 159.5/159.6 (Cq), 154.9 (Cq), 151.4 
(Cq), 148.2/148.4 (Cq), 144.1/144.2 (CH=N), 140.4/143.4 
(CH=N), 127.0/127.1 (CHAr), 115.1 (Cq), 107.1 (Cq), 
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106.9/106.8 (CHAr), 98.6/98.7 (CHAr), 56.2 (O–CH3), 
55.9 (O–CH3), 47.8/47.9 (N–CH2–CO), 29.9 (N–CH3), 
27.8/27.9 (N–CH3); HRMS (EI-MS): m/z calculated for 
C18H21N6O5 [M + H]+ 401.15679, found 401.15669.
N-(3,5-Dimethoxybenzylidene)-2-(1,3-dimethylxan‑
thin-7-yl)acethydrazide (5j) Tautomeric mixture (8:2). 
Yield 79%, white solid, m.p. >250  °C; IR (ATR diamond, 
cm−1): 3092 (–NH–), 2953 (CHAr), 1662 (–CO–NH–), 
1592 (–CH=N), 1052 (O–C); 1H-RMN (400  MHz, 
DMSO-d6): δ  =  11.78 (s, 1H, CO–NH), 8.05/8.13 (s, 
1H, CH=N), 7.96/8.06 (s, 1H, CH=N), 6.88/6.85 (d, 
J = 2.0 Hz, 2H, Ar–H), 6.56 (s, 1H, Ar–H), 5.54/5.12 (s, 
2H, CH2–CO), 3.78/3.77 (s, 6H, O–CH3), 3.45/3.44 (s, 
3H, N–CH3), 3.19 (s, 3H, N–CH3); 13C-NMR (101 MHz, 
DMSO-d6): δ = 168.4/163.3 (Cq), 161.1/161.2 (Cq), 154.8 
(Cq), 151.4 (Cq), 148.3/148.4 (Cq), 144.5/147.6 (CH=N), 
144.0/144.1 (CH=N), 136.2/136.4 (Cq), 107.1/106.8 (Cq), 
105.2/105.3 (CHAr), 102.6/102.8 (CHAr), 55.8 (O–CH3), 
47.8/47.9 (N–CH2–CO), 29.9 (N–CH3), 27.8/27.9 (N–
CH3); HRMS (EI-MS): m/z calculated for C18H21N6O5 
[M + H]+ 401.15679, found 401.15661.
N-(4-Methylbenzylidene)-2-(1,3-dimethylxanthin-7-yl)
acethydrazide (5k) Tautomeric mixture (8:2). Yield 91%, 
white solid, m.p. >250  °C; IR (ATR diamond, cm−1): 
3109 (–NH–), 2964 (CHAr), 1637 (–CO–NH–), 1544 (–
CH=N); 1H-RMN (400 MHz, DMSO-d6): δ = 11.70 (s, 
1H, CO–NH), 8.05/8.18 (s, 1H, CH=N), 8.01/8.07 (s, 
1H, CH=N), 7.62/7.58 (d, J  =  7.9  Hz, 2H, Ar–H), 7.27 
(d, J = 7.7 Hz, 2H, Ar–H)/7.27 (d, J = 7.7 Hz, 1H, Ar–H) 
and 7.24 (s, 1H, Ar–H), 5.54/5.11 (s, 2H, CH2–CO), 3.46 
(s, 3H, N–CH3), 3.20 (s, 3H, N–CH3), 2.34 (s, 3H, N–
CH3); 13C-NMR (101 MHz, DMSO-d6): δ = 168.2/163.1 
(Cq), 154.9 (Cq), 151.4 (Cq), 148.3/148.4 (Cq), 144.8/147.8 
(CH=N), 144.1/144.2 (CH=N), 140.4/140.5 (Cq), 
131.6/131.7 (Cq), 129.9 (CHAr), 127.3/127.5 (CHAr), 
107.1/106.8 (Cq), 47.8/47.9 (N–CH2–CO), 29.9 (N-CH3), 
27.8/27.9 (N-CH3), 21.4 (Ar–CH3); HRMS (EI-MS): m/z 
calculated for C17H19N6O3 [M  +  H]+ 355.15131, found 
355.15115.
Synthesis of  the theophyllinyl‑acetamido‑thiazoli‑
din‑4‑one derivatives (6a–k) Hydrazide derivatives 
(5a–k) (5  mmol) were reacted with thioglycolic acid 
(100  mmol) using freshly distillated toluene as solvent, 
according to the procedure described for other thiazo-
lidine-4-one derivatives [35]. The mixture was heated 
under reflux and stirred at 120 °C for 18 h. The reaction 
was monitored by Thin Layer Chromatography (TLC), in 
UV light at 254 nm, using ethyl acetate: methanol (9.6:0.4, 
v/v) as eluent system. At the end of the reaction, the sol-
vent was removed and the mixture was cooled at 0 °C on 
ice bath. After that, dichloromethane (100 mL) was added 
and the mixture was neutralized, under continuous stir-
ring at 0  °C, with sodium bicarbonate 10%. The organic 
layer was separated and washed with alkaline solution 
(two times with 100 mL) and then acidulated with hydro-
chloric acid 10% (300 mL). Finally, the organic phase was 
dried on anhydrous MgSO4, and it was concentrated by 
rotary evaporator under reduce pressure. The residue was 
purified on silica gel column, using ethyl acetate as eluent 
solvent.
2-Phenyl-3-[(1,3-dimethylxanthin-7-yl)acetamido]
thiazolidine-4-one (6a) Yield 50%, white solid, m.p. 
251–252  °C; IR (ATR diamond, cm−1): 3022 (–NH–), 
2926 (CHAr), 1694 (C=O), 1686 (–CO–NH–), 699(C-S); 
1H-RMN (400 MHz, CDCl3): δ = 9.50 (s, 1H, CO–NH), 
7.63 (s, 1H, N–CH–N), 7.21–7.07 (m, 5H, Ar–H), 5.79 
(s, 1H, N–CH–S), 4.96 (d, J  =  14.0  Hz, 1H, CH2–CO), 
4.54 (d, J = 14.0 Hz, 1H, CH2–CO), 3.80 (d, J = 16.0 Hz, 
1H, CH2–S), 3.67 (d, J =  16.0  Hz, 1H, CH2–S), 3.60 (s, 
3H, N–CH3), 3.22 (s, 3H, N–CH3); 13C-NMR (101 MHz, 
CDCl3): δ = 168.9 (Cq), 163.7 (Cq), 155.9 (Cq), 150.9 (Cq), 
149.1 (Cq), 141.7 (CH=N), 136.2 (Cq), 129.2 (CHAr), 
128.2 (CHAr), 128.0 (CHAr), 106.0 (Cq), 61.6 (N–CH–S), 
48.8 (N–CH2–CO), 30.02 (S–CH2–CO), 29.8 (N–
CH3), 28.1 (N-CH3); HRMS (EI-MS): m/z calculated for 
C18H19N6O4S [M + H]+ 415.11830, found 415.11817.
2-(4-Bromophenyl)-3-[(1,3-dimethylxanthin-7-yl)
acetamido]thiazolidine-4-one (6b) Yield 30%, white solid, 
m.p. >250  °C; IR (ATR diamond, cm−1): 3106 (–NH–), 
3014 (CHAr), 1698 (C=O), 1659 (–CO–NH–), 812 (C–
Br), 680 (C–S); 1H-RMN (400 MHz, CDCl3): δ = 9.58 (s, 
1H, CO–NH), 7.64 (s, 1H, N–CH–N), 7.30 (d, J = 8.1 Hz, 
2H, Ar–H), 7.08 (d, J = 8.1 Hz, 2H, Ar–H), 5.79 (s, 1H, 
N–CH–S), 4.89 (d, J =  14.0 Hz, 1H, CH2–CO), 4.60 (d, 
J  =  14.1  Hz, 1H, CH2–CO), 3.78 (d, J  =  16.0  Hz, 1H, 
CH2–S), 3.67 (d, J =  16.0  Hz, 1H, CH2–S), 3.63 (s, 3H, 
N–CH3), 3.31 (s, 3H, N–CH3); 13C-NMR (101  MHz, 
CDCl3): δ  =  168.8 (Cq), 163.8 (Cq), 156.0 (Cq), 150.5 
(Cq), 149.3 (Cq), 141.9 (CH=N), 131.5 (CHAr), 131.3 (Cq), 
129.7 (CHAr), 123.7 (Cq), 106.1 (Cq), 61.3 (N–CH–S), 
48.8 (N–CH2–CO), 30.1 (S–CH2–CO), 29.9 (N–CH3), 
28.1 (N–CH3); HRMS (EI-MS): m/z calculated for 
C18H18BrN6O4S [M + H]+ 493.02881, found 493.02831.
2-(4-Chlorophenyl)-3-[(1,3-dimethylxanthin-7-yl)
acetamido]thiazolidine-4-one (6c) Yield 29%, white solid, 
m.p. >250  °C; IR (ATR diamond, cm−1): 3111 (–NH–), 
2972 (CHAr), 1698 (C=O), 1658 (–CO–NH–), 826 (C–
Cl), 679 (C–S); 1H-RMN (250  MHz, CDCl3): δ  =  9.58 
(s, 1H, CO–NH), 7.64 (s, 1H, N–CH-N), 7.13 (s, 4H, 
Ar–H), 5.81 (s, 1H, N–CH–S), 4.90 (d, J = 14.1 Hz, 1H, 
CH2–CO), 4.59 (d, J = 14.1 Hz, 1H, CH2–CO), 3.79 (dd, 
J = 16.0 Hz, 1.2 Hz, 1H, CH2–S), 3.71–3.63 (m, 1H, CH2–
S), 3.62 (s, 3H, N–CH3), 3.30 (s, 3H, N–CH3); 13C-NMR 
(63 MHz, CDCl3): δ = 168.7 (Cq), 163.8 (Cq), 156.0 (Cq), 
150.7 (Cq), 149.3 (Cq), 141.9 (CH=N), 135.6 (Cq), 134.6 
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(Cq), 129.5 (CHAr), 128.5 (CHAr), 106.1 (Cq), 61.1 (N–
CH–S), 48.8 (N–CH2–CO), 30.0 (S–CH2–CO), 29.9 (N–
CH3), 28.0 (N-CH3); HRMS (EI-MS): m/z calculated for 
C18H18ClN6O4S [M + H]+ 449.07932, found 449.07900.
2-(4-Fluorophenyl)-3-[(1,3-dimethylxanthin-7-yl)aceta‑
mido]thiazolidine-4-one (6d) Yield 28%, white solid, m.p. 
262  °C; IR (ATR diamond, cm−1): 3116 (–NH–), 2991 
(CHAr), 1697 (C=O), 1659 (–CO–NH–), 1224 (C–F), 678 
(C–S); 1H-RMN (400 MHz, CDCl3): δ = 9.51 (s, 1H, CO–
NH), 7.63 (s, 1H, N–CH–N), 7.21–7.15 (m, 2H, Ar–H), 
6.82 (t, J  =  8.3  Hz, 2H, Ar–H), 5.83 (s, 1H, N–CH–S), 
4.91 (d, J = 14.0 Hz, 1H, CH2–CO), 4.58 (d, J = 14.1 Hz, 
1H, CH2–CO), 3.79 (d, J  =  16.0  Hz, 1H, CH2–S), 3.67 
(d, J =  16.2 Hz, 1H, CH2–S), 3.61 (s, 3H, N–CH3), 3.30 
(s, 3H, N–CH3); 13C-NMR (63 MHz, CDCl3): δ = 168.6 
(Cq), 164.3 (Cq), 163.7 (Cq), 156.0 (Cq), 150.7 (Cq), 149.3 
(CH=N), 141.8 (Cq), 131.9 (Cq), 130.2 (CHAr), 130.1 
(CHAr), 115.4 (CHAr), 115.2 (CHAr), 106.1 (Cq), 61.1 (N–
CH–S), 48.8 (N–CH2–CO), 30.0 (S–CH2–CO), 29.9 (N–
CH3), 28.0 (N–CH3); 19F-NMR (376 MHz, CDCl3, δppm): 
−110.2 (s, 1F, Ar–F); HRMS (EI-MS): m/z calculated for 
C18H18FN6O4S [M + H]+ 433.10887, found 433.10866.
2-(2-Methoxyphenyl)-3-[(1,3-dimethylxanthin-7-yl)
acetamido]thiazolidine-4-one (6e) Yield 33%, white pow-
der, m.p. 209–210  °C; IR (ATR diamond, cm−1): 3093 
(–NH–), 2991 (CHAr), 1683 (C=O), 1654 (–CO–NH–), 
1107 (O–C), 696 (C–S); 1H-RMN (250  MHz, CDCl3): 
δ = 9.46 (s, 1H, CO–NH), 7.64 (s, 1H, N–CH–N), 7.20–
7.11 (m, 1H, Ar–H), 7.07 (dd, J = 7.6, 1.5 Hz, 1H, Ar–H), 
6.73 (t, J = 7.5 Hz, 1H, Ar–H), 6.66 (d, J = 8.2 Hz, 1H, 
Ar–H), 6.10 (s, 1H, N–CH–S), 4.96 (d, J = 14.2 Hz, 1H, 
CH2–CO), 4.61 (d, J =  14.2  Hz, 1H, CH2–CO), 3.70 (s, 
3H, O–CH3), (s, 2H, CH2–S), 3.58 (s, 3H, N–CH3), 3.24 
(s, 3H, N–CH3); 13C-NMR (63 MHz, CDCl3): δ = 169.7 
(Cq), 163.6 (Cq), 157.5 (Cq), 155.9 (Cq), 150.9 (Cq), 149.0 
(Cq), 141.8 (CH=N), 130.1 (CHAr), 128.9 (CHAr), 124.7 
(Cq), 120.2 (CHAr), 110.3 (CHAr), 106.1 (Cq), 57.0 (N–
CH–S), 55.5 (O–CH3), 48.7 (N–CH2–CO), 30.0 (S–CH2–
CO), 29.8 (N–CH3), 28.1 (N–CH3); HRMS (EI-MS): m/z 
calculated for C19H21N6O5S [M + H]+ 445.12886, found 
445.12838.
2-(4-Methoxyphenyl)-3-[(1,3-dimethylxanthin-7-yl)
acetamido]thiazolidine-4-one (6f) Yield 37%, white pow-
der, m.p. 239–240  °C; IR (ATR diamond, cm−1): 3106 
(–NH–), 2961 (CHAr), 1697 (C=O), 1657 (–CO–NH–), 
1114 (O–C), 680(C–S); 1H-RMN (400  MHz, CDCl3): 
δ  =  9.57 (s, 1H, CO–NH), 7.63 (s, 1H, N–CH–N), 
7.06 (d, J = 8.1 Hz, 2H, Ar–H), 6.60 (d, J = 8.1 Hz, 2H, 
Ar–H), 5.77 (s, 1H, N–CH–S), 4.94 (d, J = 14.0 Hz, 1H, 
CH2–CO), 4.54 (d, J =  14.0 Hz, 1H, CH2–CO), 3.78 (d, 
J =  17.1 Hz, 1H, CH2–S), 3.75 (s, 3H, O–CH3), 3.65 (d, 
J =  16.0  Hz, 1H, CH2–S), 3.60 (s, 3H, N–CH3), 3.25 (s, 
3H, N–CH3); 13C-NMR (101  MHz, CDCl3): δ  =  168.8 
(Cq), 163.6 (Cq), 160.4 (Cq), 156.0 (Cq), 150.7 (Cq), 149.2 
(Cq), 141.7 (CH=N), 129.5 (CHAr), 127.4 (Cq), 113.4 
(CHAr), 106.1 (Cq), 61.4 (N–CH–S), 55.2 (O–CH3), 
48.9 (N–CH2–CO), 30.1 (S–CH2–CO), 29.9 (N–CH3), 
28.0 (N–CH3); HRMS (EI-MS): m/z calculated for 
C19H21N6O5S [M + H]+ 445.12886, found 445.128533.
2-(3-Methoxyphenyl)-3-[(1,3-dimethylxanthin-7-yl)
acetamido]thiazolidine-4-one (6g) Yield 50%, white solid, 
m.p. 199–200 °C; IR (ATR diamond, cm−1): 3013 (–NH–), 
2951 (CHAr), 1701 (C=O), 1654 (–CO–NH–), 1175 (O–C), 
694 (C–S); 1H-RMN (400  MHz, CDCl3): δ =  9.56(s, 1H, 
CO–NH), 7.64 (s, 1H, N–CH–N), 7.00 (t, J = 7.9 Hz, 1H, 
Ar–H), 6.70 (d, J = 7.6 Hz, 2H, Ar–H), 6.62 (s, 1H, Ar–H), 
5.75 (s, 1H, N–CH–S), 4.99 (d, J = 14.0 Hz, 1H, CH2–CO), 
4.53 (d, J = 14.0 Hz, 1H, CH2–CO), 3.80 (d, J = 16.0 Hz, 
1H, CH2–S), 3.70 (s, 3H, O–CH3), 3.67 (d, J = 16.2 Hz, 1H, 
CH2–S), 3.60 (s, 3H, N–CH3), 3.23 (s, 3H, N–CH3); 13C-
NMR (101 MHz, CDCl3): δ = 168.9 (Cq), 163.7 (Cq), 157.6 
(Cq), 156.0 (Cq), 150.9 (Cq), 149.1 (Cq), 141.6 (CH=N), 
137.6 (Cq), 129.2 (CHAr), 120.1 (CHAr), 115.3 (CHAr), 112.6 
(CHAr), 106.0 (Cq), 61.6 (N–CH–S), 55.2 (O–CH3), 48.9 
(N–CH2–CO), 30.0 (S–CH2–CO), 29.8 (N–CH3), 28.0 
(N–CH3); HRMS (EI-MS): m/z calculated for C19H21N6O5S 
[M + H]+ 445.12886, found 445.12836.
2-(2,3-Dimethoxyphenyl)-3-[(1,3-dimethylxanthin-
7-yl)acetamido]thiazolidine-4-one (6h) Yield 50%, white 
powder, m.p. 247–248 °C; IR (ATR diamond, cm−1): 3110 
(–NH–), 2983 (CHAr), 1695 (C=O), 1651 (–CO–NH–), 
1175 (O–C), 692 (C–S); 1H-RMN (400  MHz, CDCl3): 
δ =  9.52 (s, 1H, CO–NH), 7.64 (s, 1H, N–CH–N), 6.91 
(t, J = 7.9 Hz, 1H, Ar–H), 6.81 (d, J = 7.8 Hz, 1H, Ar–H), 
6.76 (d, J =  8.1  Hz, 1H, Ar–H), 6.09 (s, 1H, N–CH–S), 
4.99 (d, J = 14.0 Hz, 1H, CH2–CO), 4.59 (d, J = 14.1 Hz, 
1H, CH2–CO), 3.80 (s, 3H, O–CH3), 3.72 (d, J = 9.1 Hz, 
2H, CH2–S), 3.59 (s, 6H, O–CH3, N–CH3), 3.25 (s, 3H, 
N–CH3); 13C-NMR (101  MHz, CDCl3): δ  =  169.34 
(Cq), 163.54 (Cq), 156.06 (Cq), 152.31 (Cq), 151.05 (Cq), 
149.21 (Cq), 147.6 (Cq), 141.76 (CH=N), 130.03 (Cq), 
123.83 (CHAr), 120.02 (CHAr), 112.71 (CHAr), 106.26 
(Cq), 61.00 (N–CH–S), 56.20 (O–CH3), 55.87 (O–CH3), 
48.94 (N–CH2–CO), 29.98 (S–CH2–CO), 29.83 (N–
CH3), 28.13 (N–CH3); HRMS (EI-MS): m/z calculated for 
C20H23N6O6S [M + H]+ 475.13943, found 475.139544.
2-(2,4-Dimethoxyphenyl)-3-[(1,3-dimethylxanthin-
7-yl)acetamido]thiazolidine-4-one (6i) Yield 6%, yellow 
powder, m.p. >250  °C; IR (ATR diamond, cm−1): 3113 
(–NH–), 2966 (CHAr), 1684 (C=O), 1616 (–CO–NH–), 
1022 (O–C), 665 (C–S); 1H-RMN (400  MHz, CDCl3): 
δ = 9.50 (s, 1H, CO–NH), 7.64 (s, 1H, CH=N), 6.99 (d, 
J = 8.4 Hz, 1H, Ar–H), 6.26–6.21 (m, 1H, Ar–H), 6.19 (s, 
1H, Ar–H), 6.06 (s, 1H, N–CH–S), 4.95 (d, J = 14,3 Hz, 
1H, CH2–CO), 4.61 (d, J = 14.3 Hz, 1H, CH2–CO), 3.74 
(s, 3H, O–CH3), 3.71–3.61 (m, 5H, CH2–S, O–CH3), 
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3.58 (s, 3H, N–CH3), 3.26 (s, 3H, N–CH3); 13C-NMR 
(101  MHz, CDCl3): δ  =  169.6 (Cq), 163.6 (Cq), 161.6 
(Cq), 158.8 (Cq), 155.9 (Cq), 150.8 (Cq), 149.0 (Cq), 141.9 
(CH=N), 130.0 (CHAr), 116.6 (Cq), 106.1 (Cq), 104.0 
(CHAr), 97.9 (CHAr), 56.9 (N–CH–S), 55.5 (O–CH3), 55.3 
(O–CH3), 48.7 (N–CH2–CO), 30.1 (S–CH2–CO), 29.8 
(N–CH3), 28.0 (N–CH3); HRMS (EI-MS): m/z calculated 
for C20H23N6O6S [M + H]+ 475.13943, found 475.13968.
2-(3,5-Dimethoxyphenyl)-3-[(1,3-dimethylxanthin-
7-yl)acetamido]thiazolidine-4-one (6j) Yield 54%, white 
solid, m.p. 247–248  °C; IR (ATR diamond, cm−1): 3045 
(-NH- ), 2994 (CHAr), 1682 (C=O), 1655 (–CO–NH–), 
1052 (O-C), 671 (C-S); 1H-RMN (400  MHz, CDCl3): 
δ = 9.65 (s, 1H, CO–NH), 7.64 (s, 1H, N–CH–N), 6.23 (s, 
3H, Ar–H), 5.69 (s, 1H, N–CH–S), 5.02 (d, J = 13.9 Hz, 
1H, CH2–CO), 4.52 (d, J = 13.9 Hz, 1H, CH2–CO), 3.79 
(d, J =  15.9 Hz, 1H, CH2–S), 3.68 (s, 6H, O–CH3), 3.64 
(s, CH2–S), 3.59 (s, 3H, N–CH3), 3.24 (s, 3H, N–CH3); 
13C-NMR (101  MHz, CDCl3): δ  =  169.03 (Cq), 163.7 
(Cq), 160.8 (Cq), 156.0 (Cq), 150.9 (Cq), 149.1 (Cq), 141.5 
(CH=N), 138.3 (Cq), 106.0 (Cq), 105.2 (CHAr), 101.6 
(CHAr), 61.7 (N–CH–S), 55.3 (O–CH3), 48.9 (N–CH2–
CO), 30.0 (S–CH2–CO), 29.8 (N–CH3), 27.9 (N–CH3); 
HRMS (EI-MS): m/z calculated for C20H23N6O6S 
[M + H]+ 475.13943, found 475.13967.
2-(4-Methylphenyl)-3-[(1,3-dimethylxanthin-7-yl)
acetamido]thiazolidine-4-one (6k) Yield 52%, white 
powder, m.p. >250; IR (ATR diamond, cm−1): 3106 (–
NH–), 2920 (CHAr), 1696 (C=O), 1656 (–CO–NH–), 
1021 (O–C), 680 (C–S); 1H-RMN (400  MHz, CDCl3): 
δ  =  9.54 (s, 1H, CO–NH), 7.64 (s, 1H, N–CH–N), 
7.02 (d, J = 7.7 Hz, 2H, Ar–H), 6.93 (d, J = 7.8 Hz, 2H, 
Ar–H), 5.73 (s, 1H, N–CH–S), 4.95 (d, J = 14.0 Hz, 1H, 
CH2–CO), 4.56 (d, J =  14.1 Hz, 1H, CH2–CO), 3.78 (d, 
J = 16.0 Hz, 1H, CH2–S), 3.67 (d, J = 16.1 Hz, 1H, CH2–
S), 3.60 (s, 3H, N–CH3), 3.23 (s, 3H, N–CH3), 2.28 (s, 3H, 
Ar–CH3); 13C-NMR (101 MHz, CDCl3): δ = 169.0 (Cq), 
163.6 (Cq), 156.0 (Cq), 150.8 (Cq), 149.1 (Cq), 141.8 (Cq), 
139.8 (CH=N), 133.1 (Cq), 128.9 (CHAr), 128.0 (CHAr), 
106.2 (Cq), 61.6 (N–CH–S), 48.9 (N–CH2–CO), 30.0 
(S–CH2–CO), 29.9 (N–CH3), 28.0 (N–CH3), 21.2 (Ar–
CH3); HRMS (EI-MS): m/z calculated for C19H21N6O4S 
[M + H]+ 429.13395, found 429.13383 (Additional file 1).
Biological evaluation
The antioxidant activity was estimated using in  vitro 
tests: DPPH and ABTS radical scavenging ability and 
total antioxidant capacity.
DPPH radical scavenging assay The antiradical activity 
against 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) was 
measured as described in [32] with slight modifications. 
Different samples of the tested compounds (50, 100, 150, 
200, 250 μL) from a stock solution (20 mg/mL in DMSO) 
were mixed with DMSO to obtain 1300  μL, and then 
DPPH in methanol (1200 μL, 15 μM) was added. The final 
concentrations of the compound in the test tube were 0.4, 
0.8, 1.2, 1.6, and 2 mg/mL, respectively. The mixture was 
left for 30 min in the darkness and, after that, the absorb-
ance was measured at 517  nm against a blank solution 
(methanol). The radical scavenging capacity was calcu-
lated using the following equation:
where Acontrol is the absorbance of the mixture of 1300 μL 
DMSO and 1200  μL DPPH after 30  min; Asample is the 
absorbance of the sample after 30 min.
For the most active compounds, the effective concen-
tration (EC50) was calculated by linear regression analy-
sis. The theophylline (parent compound) and ascorbic 
acid (vitamin C) were used as reference and positive con-
trol, respectively. All tests were performed in triplicate.
ABTS radical scavenging assay ABTS+ radicals were 
activated by reacting of ABTS (2,2′-azinobis(3-ethylben-
zthiazoline-6-sulphonic acid)) (7  mM) with ammonium 
persulphate (2.45 mM) and the mixture was left for 16 h in 
the darkness, at room temperature. The resulted ABTS·+ 
solution was diluted with ethanol to obtain an absorb-
ance value of 0.7 ± 0.02 at 734 nm as described in [33]. 
Different samples of the tested compounds (50, 100, 150, 
200 μL) from a stock solution (10 mg/mL in DMSO) were 
mixed with DMSO to obtain 200  μL, and then freshly 
ABTS·+ solution (1800 μL) was added. The final concen-
trations of the compound in the test tube were 0.25, 0.50, 
0.75 and 1 mg/mL, respectively. The mixture was stirred 
and left in the dark for 6 min., at room temperature, and 
the absorbance was measured at 734 nm. The radical scav-
enging capacity was calculated according to the following 
equation:
where Acontrol is the absorbance of the mixture of 200 μL 
DMSO and 1800  μL ABTS·+ after 6  min; Asample is the 
absorbance of sample after 6 min.
For the most active compounds the effective concentra-
tion (EC50) was calculated by linear regression analysis. 
The theophylline (parent compound) and ascorbic acid 
(vitamin C) were used as reference and positive control, 
respectively. All tests were performed in triplicate.
Phosphomolybdenum reducing antioxidant power (PRAP) 
assay The phosphomolybdenum method was used 
according to the procedure described in [34] with few 
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modifications. Different samples of the tested compounds 
(25, 50, 75, 100, 150 μL) from a stock solution (2.5 mg/
mL in DMSO) were mixed with DMSO to obtain 150 μL, 
and then 2  mL of reagent solution (0.6  M sulfuric acid, 
28 mM sodium phosphate, 4 mM ammonium molybdate) 
were added. The test tubes were closed and incubated in 
the oven at 95 °C, for 90 min. After cooling at room tem-
perature, the absorbance was measured at 695 nm against 
a blank solution (DMSO with 2  mL reagent solution). 
The final concentrations of the compound in the test tube 
were 0.0291, 0.0582, 0.0872, 0.1163 and 0.1745  mg/mL. 
EC50 was calculated for all the tested compounds. Theo-
phylline (parent compound) and ascorbic acid (vitamin C) 
were used as reference and positive control, respectively. 
All tests were performed in triplicate.
Statistical analysis All antioxidant assays were car-
ried out in triplicate. Data were analyzed by an analysis 
of variance (ANOVA) (p  <  0.05) and were expressed by 
mean  ±  SD. The EC50 values were calculated by linear 
interpolation between the values registered above and 
below 50% activity.
Conclusions
In this research new xanthine derivatives based on thi-
azolidine-4-one scaffold have been synthetized. The 
intermediate and final compounds were characterized 
in terms of physical properties and their structure was 
proved using spectral methods (FT-IR, 1H-NMR, 13C-
NMR, 19F-NMR, HRMS). The antioxidant potential was 
evaluated using in vitro assays: DPPH and ABTS radical 
scavenging ability and phosphomolybdenum reducing 
antioxidant power assays. Some of the thiazolidin-4-one 
derivatives showed improved antioxidant effects in com-
parison to the corresponding hydrazones and parent 
compound, theophylline. A good antiradical scavenging 
effect (DPPH, ABTS) was shown by 6f (R=4-OCH3), 6d 
(4-F), 6c (4-Cl) and 6k (4-CH3). The compounds 6c and 
6k showed also a high phosphomolybdenum reducing 
antioxidant power. The preliminary results support the 
antioxidant potential of some thiazolidine-4-one deriva-
tives and motivate our next research focused on strepto-
zotocin-induced diabetic rat model.
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